
Kristi Rosa
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com
Articles
Firstline Nivolumab/Chemotherapy Continues To Outperform Chemotherapy Alone for Advanced Gastric/GEJ/Esophageal Cancer At 3-Year Follow-Up
January 21, 2023
Article
In an all-randomized population of patients with advanced gastric cancer, gastroesophageal junction, or esophageal adenocarcinoma, adding nivolumab to chemotherapy yielded a 21% reduction in the risk of death.
Nadofaragene Firadenovec Gets Go-Ahead in High-Risk Non–Muscle Invasive Bladder Cancer
January 03, 2023
Article
The FDA has approved nadofaragene firadenovec-vncg for patients with high-risk non-muscle invasive bladder cancer.
Mosunetuzumab Gets Green Light for Adults With Relapsed/Refractory Follicular Lymphoma
January 03, 2023
Article
Mosunetuzumab is now an FDA approved treatment for patients with relapsed or refractory follicular lymphoma who have already undergone 2 or more lines or systemic therapy.
Atezolizumab Gets Green Light in Alveolar Soft Part Sarcoma
December 13, 2022
Article
Atezolizumab has been granted FDA approval for patients aged 2 years and older with unresectable or metastatic alveolar soft part sarcoma.
Ponatinib Outperforms Imatinib in Newly Diagnosed Philadelphia Chromosome+ Acute Lymphoblastic Leukemia
November 27, 2022
Article
Combining ponatinib with reduced-intensity chemotherapy elicited a high rate of minimal residual disease (MRD)-negative complete remissions and no new safety signals in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.
Adding Eganelisib to Standard of Care Therapy Shows Promise in Frontline TNBC
November 18, 2022
Article
The 1-year PFS rate among patients with metastatic, triple-negative breast cancer who received a combination eganelisib, atezolizumab, and nab-paclitaxel was 36%.
Brentuximab Vedotin Gets Green Light for High-Risk Hodgkin Lymphoma in Pediatric Patients
November 16, 2022
Article
The FDA has approved brentuximab vedotin (Adcetris) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients with classical Hodgkin lymphoma.
Durvalumab/Tremelimumab/Chemotherapy Combination Approved for NSCLC Indication
November 15, 2022
Article
The FDA has given the go-ahead to a combination of tremelimumab-actl (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy for patients with non-small cell lung cancer and no EGFR mutations or ALK aberrations.
Oral MEK Inhibitor, Cobimetinib, Receives FDA Approval for Histiocytic Neoplasms
November 04, 2022
Article
Cobimetinib is now an FDA-approved therapy for patients with histiocytic neoplasms.
Teclistamab-cqyv Snags Accelerated Approval for Relapsed or Refractory Multiple Myeloma
October 27, 2022
Article
Patients with multiple myeloma who have already undergone 4 lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, may now receive treatment with teclistamab-cqyv (Tecvayli).